title: Alkylhydroperoxide reductase of Helicobacter pylori as a biomarker for gastric patients with different pathological manifestations.
abstract: The development of various gastrointestinal diseases was suggested to be associated with chronic inflammation as a consequence of Helicobacter pylori (H. pylori) infection. Our previous studies showed that an antioxidant protein alkylhydroperoxide reductase (AhpC) is an abundant and important antioxidant protein present in H. pylori. In this study we have explored the potential of utilizing antibodies to AhpC for detection of patients who are at high risks of evolving into severe outcomes of gastric malignancies after H. pylori infection. The correlation between AhpC and extents of inflammatory damage in tissues was demonstrated by immunoblotting assays and endoscopic examinations. Oxidative stress-induced high-molecular-weight (HMW) AhpC with chaperone activity in vivo was further investigated by co-immunoprecipitation, 2-dimensional gel electrophoresis (2-DE) followed by nano-liquid chromatography coupled tandem mass spectrometry (nanoLC-MS/MS). We found AhpC was consistently expressed in higher amounts in H. pylori strains isolated from patients with gastric cancer (GC) than gastritis (GA). Immunological analysis of seropositivity for AhpC indicated that positive diagnostic rates for H. pylori-infected patients with GA, gastric ulcer (GU) and GC were 68% (15/22), 100% (50/50) and 100% (50/50), respectively. In great contrast to low-molecular-weight (LMW) AhpC, HMW AhpC with chaperone function was found to distribute inside of H. pylori cells. We also found that LMW forms of AhpC were recognized by serum antibodies from GA patients whereas HMW forms of AhpC reacted mainly with those from GU and GC patients. Based on the significant difference between AhpC isolated from strains of GC and GA, it is conceivable that AhpC of H. pylori may prove to be useful as a prognostic or diagnostic protein marker to monitor varied clinical manifestations of gastrointestinal patients infected with H. pylori.
authors: Graduate Institute of Medicine, Center for Research Resources and Development, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
authors: Chun-Hao
authors: CH
authors: Huang
authors: Ming-Hong
authors: MH
authors: Chuang
authors: Wan-Lin
authors: WL
authors: Lo
authors: Ming-Shiang
authors: MS
authors: Wu
authors: Yuan-Heng
authors: YH
authors: Wu
authors: Deng-Chyang
authors: DC
authors: Wu
authors: Shyh-Horng
authors: SH
authors: Chiou
mesh_terms: D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D015180:Electrophoresis, Gel, Two-Dimensional; D005756:Gastritis / Q000175:diagnosis / Q000382:microbiology; D005838:Genotype; D016481:Helicobacter Infections / Q000175:diagnosis / Q000382:microbiology*; D016480:Helicobacter pylori / Q000201:enzymology* / Q000235:genetics / Q000648:ultrastructure; D006801:Humans; D015151:Immunoblotting; D046529:Microscopy, Electron, Transmission; D018832:Molecular Chaperones / Q000378:metabolism; D008970:Molecular Weight; D018384:Oxidative Stress; D054464:Peroxiredoxins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D013276:Stomach Ulcer / Q000175:diagnosis / Q000382:microbiology
chemical_list: D001426:Bacterial Proteins; D015415:Biomarkers; D018832:Molecular Chaperones; D054464:Peroxiredoxins